Casper H J Van Eijck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6946419/publications.pdf

Version: 2024-02-01

		66234	49773
156	8,640	42	87
papers	citations	h-index	g-index
156	156	156	8659
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	5.1	719
2	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 2020, 38, 1763-1773.	0.8	665
3	Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. Lancet, The, 2018, 391, 51-58.	6.3	504
4	Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD). Annals of Surgery, 2019, 269, 2-9.	2.1	401
5	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clinical Cancer Research, 2017, 23, 4617-4624.	3. 2	399
6	Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. Lancet, The, 2015, 386, 1261-1268.	6.3	276
7	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology, 2022, 40, 1220-1230.	0.8	274
8	Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS). Annals of Surgery, 2019, 269, 937-943.	2.1	257
9	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	3.0	223
10	International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. JAMA Surgery, 2018, 153, e183617.	2.2	213
11	Risk of Recurrent Pancreatitis and Progression to Chronic Pancreatitis After a First Episode of Acute Pancreatitis. Clinical Gastroenterology and Hepatology, 2016, 14, 738-746.	2.4	211
12	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). Annals of Surgery, 2019, 269, 10-17.	2.1	211
13	The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels. Annals of Surgery, 2019, 270, 139-146.	2.1	179
14	Superiority of Step-up Approach vs Open Necrosectomy in Long-term Follow-up of Patients With Necrotizing Pancreatitis. Gastroenterology, 2019, 156, 1016-1026.	0.6	145
15	Effect of Early Surgery vs Endoscopy-First Approach on Pain in Patients With Chronic Pancreatitis. JAMA - Journal of the American Medical Association, 2020, 323, 237.	3.8	138
16	Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials, 2016, 17, 127.	0.7	131
17	Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 681-690.	3.7	126
18	Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 453-463.	3.3	125

#	Article	IF	CITATIONS
19	The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis. Surgery, 2014, 155, 442-448.	1.0	101
20	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2018, 267, 1148-1154.	2.1	101
21	Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Theranostics, 2016, 6, 1821-1832.	4.6	100
22	Nationwide trends in incidence, treatmentÂand survival of pancreatic ductal adenocarcinoma. European Journal of Cancer, 2020, 125, 83-93.	1.3	98
23	Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. Hpb, 2017, 19, 919-926.	0.1	97
24	Management of Severe Pancreatic Fistula After Pancreatoduodenectomy. JAMA Surgery, 2017, 152, 540.	2.2	96
25	Postoperative Complications, Inâ€Hospital Mortality and 5â€Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review. World Journal of Surgery, 2016, 40, 729-748.	0.8	93
26	Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. World Journal of Surgery, 2016, 40, 715-728.	0.8	91
27	Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. Hpb, 2018, 20, 759-767.	0.1	85
28	Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut, 2022, 71, 1152-1160.	6.1	84
29	Timing of catheter drainage in infected necrotizing pancreatitis. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 306-312.	8.2	83
30	A Nationwide Comparison of Laparoscopic and Open Distal Pancreatectomy for Benign and Malignant Disease. Journal of the American College of Surgeons, 2015, 220, 263-270e1.	0.2	78
31	Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. Hpb, 2016, 18, 49-56.	0.1	72
32	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta Oncol \tilde{A}^3 gica, 2018, 57, 1655-1662.	0.8	70
33	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. Hpb, 2020, 22, 233-240.	0.1	66
34	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 2019, 11, 976.	1.7	63
35	The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis. Surgery, 2016, 159, 688-699.	1.0	59
36	Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. Lancet, The, 2022, 399, 1867-1875.	6.3	59

#	Article	IF	CITATIONS
37	Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome. Neoplasia, 2014, 16, 868-873.	2.3	55
38	Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 103-114.	2.2	54
39	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. Annals of Surgery, 2020, 272, 731-737.	2.1	49
40	Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. Annals of Surgical Oncology, 2016, 23, 585-591.	0.7	48
41	Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2018, 267, 352-356.	2.1	46
42	Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. Surgery, 2019, 166, 1017-1026.	1.0	43
43	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. Annals of Surgery, 2020, 271, e102-e104.	2.1	43
44	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 588.	1.7	42
45	Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine, 2019, 17, 100200.	3.2	41
46	Potent Inhibitory Effects of Type I Interferons on Human Adrenocortical Carcinoma Cell Growth. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4537-4543.	1.8	40
47	Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. Annals of Surgical Oncology, 2016, 23, 2002-2009.	0.7	40
48	Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial. Trials, 2017, 18, 166.	0.7	40
49	Detection bias may be the main cause of increased cancer incidence among diabetics: Results from the Rotterdam Study. European Journal of Cancer, 2014, 50, 2449-2455.	1.3	38
50	Impact of Complications After Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission. Annals of Surgery, 2022, 275, e222-e228.	2.1	38
51	Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial. BMC Gastroenterology, 2015, 15, 20.	0.8	36
52	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
53	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Annals of Surgical Oncology, 2020, 27, 2516-2524.	0.7	36
54	Impact of centralization of pancreatoduodenectomy on reported radical resections rates in a nationwide pathology database. Hpb, 2015, 17, 736-742.	0.1	34

#	Article	IF	Citations
55	Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial. Trials, 2016, 17, 5.	0.7	34
56	Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. Viruses, 2015, 7, 2980-2998.	1.5	33
57	Early recognition of clinically relevant postoperative pancreatic fistula: a systematic review. Hpb, 2020, 22, 1-11.	0.1	32
58	Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 56816-56828.	0.8	32
59	Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve followâ€up after curative surgical resection of wellâ€differentiated pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 2018, 118, 37-48.	0.8	30
60	New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis. Surgery, 2018, 164, 6-16.	1.0	27
61	Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). Annals of Surgery, 2022, 275, 979-984.	2.1	26
62	Video-assisted thoracic lobectomy <i>versus</i> stereotactic body radiotherapy for stage I nonsmall cell lung cancer in elderly patients: a propensity matched comparative analysis. European Respiratory Journal, 2019, 53, 1801561.	3.1	24
63	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. Annals of Surgery, 2021, 274, 721-728.	2.1	24
64	Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis. Hpb, 2016, 18, 559-566.	0.1	23
65	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A populationâ€based study. Cancer Medicine, 2018, 7, 4943-4951.	1.3	23
66	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. Molecular Oncology, 2020, 14, 2176-2189.	2.1	23
67	mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Letters, 2014, 346, 309-317.	3.2	22
68	Changes in treatment patterns and survival in elderly patients with stage I non–small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery. European Journal of Cancer, 2018, 101, 30-37.	1.3	22
69	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers, 2019, 11, 93.	1.7	22
70	The bigger picture of shared decision making: A service design perspective using the care path of locally advanced pancreatic cancer as a case. Cancer Medicine, 2021, 10, 5907-5916.	1.3	22
71	Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Trials, 2021, 22, 608.	0.7	22
72	Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 6602-6612.	3.2	22

#	Article	IF	CITATIONS
73	Potentials of Interferon Therapy in the Treatment of Pancreatic Cancer. Journal of Interferon and Cytokine Research, 2015, 35, 327-339.	0.5	21
74	Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial. Trials, 2020, 21, 389.	0.7	21
75	Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria. Annals of Surgical Oncology, 2021, 28, 2325-2336.	0.7	21
76	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. European Journal of Surgical Oncology, 2021, 47, 2525-2532.	0.5	21
77	FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Journal of the National Cancer Institute, 2022, 114, 695-703.	3.0	20
78	Search for Early Pancreatic Cancer Blood Biomarkers in Five European Prospective Population Biobanks Using Metabolomics. Endocrinology, 2019, 160, 1731-1742.	1.4	19
79	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 8297-8308.	0.7	19
80	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. Hpb, 2021, 23, 413-421.	0.1	18
81	Type I interferons in pancreatic cancer and development of new therapeutic approaches. Critical Reviews in Oncology/Hematology, 2021, 159, 103204.	2.0	18
82	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Hpb, 2021, 23, 25-36.	0.1	16
83	Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. British Journal of Surgery, 2021, 109, 96-104.	0.1	16
84	The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies. Hpb, 2021, 23, 1321-1331.	0.1	16
85	Impact of parathyroidectomy for primary hyperparathyroidism on quality of life: A caseâ€control study using Short Form Health Survey 36. Head and Neck, 2016, 38, 1213-1220.	0.9	15
86	Clinical relevance of performing endoscopic ultrasoundâ€guided fineâ€needle biopsy for pancreatic neuroendocrine tumors less than 2 cm. Journal of Surgical Oncology, 2020, 122, 1393-1400.	0.8	15
87	Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A systematic review and meta-analysis. Pancreatology, 2022, 22, 235-243.	0.5	15
88	International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. European Journal of Surgical Oncology, 2020, 46, 796-803.	0.5	14
89	RNA from stabilized whole blood enables more comprehensive immune gene expression profiling compared to RNA from peripheral blood mononuclear cells. PLoS ONE, 2020, 15, e0235413.	1.1	14
90	Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 704-711.	2.3	14

#	Article	IF	Citations
91	Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort. Neuroendocrinology, 2021, 111, 705-717.	1.2	13
92	Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only. Annals of Surgery, 2021, 274, 729-735.	2.1	13
93	The Placental Innate Immune System Is Altered in Early-Onset Preeclampsia, but Not in Late-Onset Preeclampsia. Frontiers in Immunology, 2021, 12, 780043.	2.2	13
94	Liver Contrast-Enhanced Ultrasound Improves Detection ofÂLiver Metastases in Patients with Pancreatic or Periampullary Cancer. Ultrasound in Medicine and Biology, 2015, 41, 3063-3069.	0.7	12
95	Pancreatoduodenectomy with colon resection for cancer: A nationwide retrospective analysis. Surgery, 2016, 160, 145-152.	1.0	12
96	C-reactive protein is superior to white blood cell count for early detection of complications after pancreatoduodenectomy: a retrospective multicenter cohort study. Hpb, 2020, 22, 1504-1512.	0.1	12
97	Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Frontiers in Oncology, 2020, 10, 1112.	1.3	12
98	Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. Cancer Medicine, 2020, 9, 9385-9395.	1.3	12
99	Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort. Annals of Surgical Oncology, 2021, 28, 4387-4399.	0.7	12
100	Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	12
101	Postoperative parathyroid hormone levels as a predictor for persistent hypoparathyroidism. European Journal of Endocrinology, 2020, 183, 149-159.	1.9	12
102	Incidence and impact of postoperative pancreatic fistula after minimally invasive and open distal pancreatectomy. Surgery, 2022, 171, 1658-1664.	1.0	12
103	Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. Hpb, 2015, , n/a-n/a.	0.1	11
104	Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. BMC Cancer, 2020, 20, 913.	1.1	11
105	Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer. Clinica Chimica Acta, 2020, 505, 183-189.	0.5	11
106	Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1354-1363.	2.3	11
107	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Frontiers in Genetics, 2021, 12, 693933.	1.1	10
108	Age and prognosis in patients with pancreatic cancer: a population-based study. Acta $Oncol\tilde{A}^3$ gica, 2022, 61, 286-293.	0.8	10

#	Article	IF	CITATIONS
109	Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. Pancreatology, 2020, 20, 1723-1731.	0.5	9
110	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta Oncol \tilde{A}^3 gica, 2020, 59, 705-712.	0.8	9
111	Surgical management and pathological assessment of pancreatoduodenectomy with venous resection: an international survey among surgeons and pathologists. Hpb, 2021, 23, 80-89.	0.1	9
112	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. International Journal of Molecular Sciences, 2021, 22, 10902.	1.8	9
113	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Frontiers in Oncology, 2022, 12, 839779.	1.3	9
114	Circulating <i>TP53 </i> mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110337.	1.4	8
115	Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3203-3214.	3.3	8
116	Diagnostic value of a pancreatic mass on computed tomography in patients undergoing pancreatoduodenectomy for presumed pancreatic cancer. Surgery, 2015, 158, 173-182.	1.0	7
117	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. Strahlentherapie Und Onkologie, 2017, 193, 630-638.	1.0	7
118	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Familial Cancer, 2020, 19, 247-258.	0.9	7
119	The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. Biomedicines, 2022, 10, 517.	1.4	7
120	Longâ€term survival after resection for nonâ€pancreatic periampullary cancer followed by adjuvant intraâ€arterial chemotherapy and concomitant radiotherapy. Hpb, 2015, 17, 573-579.	0.1	6
121	Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. Surgical Pathology Clinics, 2016, 9, 539-545.	0.7	6
122	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers, 2021, 13, 2242.	1.7	6
123	International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2022, 112, 571-579.	1.2	6
124	Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients. IScience, 2021, 24, 103415.	1.9	6
125	Routine abdominal drainage after distal pancreatectomy: meta-analysis. British Journal of Surgery, 2022, 109, 486-488.	0.1	6
126	Absence or low IGFâ€1Râ€expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection. Journal of Surgical Oncology, 2015, 111, 1047-1053.	0.8	5

#	Article	IF	Citations
127	Patients with chronic mesenteric ischemia have an altered sublingual microcirculation. Clinical and Experimental Gastroenterology, 2018, Volume 11, 405-414.	1.0	5
128	Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?. Cancers, 2021, 13, 2896.	1.7	5
129	The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. Hpb, 2022, 24, 443-451.	0.1	5
130	Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. Journal of Oncology, 2022, 2022, 1-9.	0.6	5
131	Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Applied Sciences (Switzerland), 2019, 9, 4784.	1.3	4
132	Predicting Successful Catheter Drainage in Patients With Pancreatic Fistula After Pancreatoduodenectomy. Pancreas, 2019, 48, 811-816.	0.5	4
133	The value of serum amylase and drain fluid amylase to predict postoperative pancreatic fistula after pancreatoduodenectomy: a retrospective cohort study. Langenbeck's Archives of Surgery, 2021, 406, 2333-2341.	0.8	4
134	Differential Expression of BOC, SPOCK2, and GJD3 Is Associated with Brain Metastasis of ER-Negative Breast Cancers. Cancers, 2021, 13, 2982.	1.7	4
135	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2342-2345.	1.1	4
136	External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	4
137	Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). JAMA Oncology, 2022, 8, 929.	3.4	4
138	Pancreatic resection in the pediatric, adolescent and young adult population: nationwide analysis on complications. Hpb, 2021, 23, 1175-1184.	0.1	3
139	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. Hpb, 2021, 23, 1886-1896.	0.1	3
140	Sensitivity of CT, MRI, and EUS-FNA/B in the preoperative workup of histologically proven left-sided pancreatic lesions. Pancreatology, 2022, 22, 136-141.	0.5	3
141	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Scientific Reports, 2021, 11, 7570.	1.6	2
142	Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. Supportive Care in Cancer, 2022, 30, 2407-2415.	1.0	2
143	Trends in Staging, Treatment, and Survival in Colorectal Cancer Between 1990 and 2014 in the Rotterdam Study. Frontiers in Oncology, 2022, 12, 849951.	1.3	2
144	Immunomodulatory antitumor effect of interferonâ€'beta combined with gemcitabine in pancreatic cancer. International Journal of Oncology, 2022, 61, .	1.4	2

#	Article	IF	CITATIONS
145	Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report. Journal of Pancreatic Cancer, 2017, 3, 13-14.	1.6	1
146	A Rare Tumor in the Common Bile Duct: A Case Report. Journal of Pancreatic Cancer, 2017, 3, 10-12.	1.6	1
147	Management of postoperative pancreatic fistula after pancreatoduodenectomy: high mortality after completion pancreatectomy. Hpb, 2018, 20, 1223.	0.1	1
148	ASO Visual Abstract: Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer—A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2021, 28, 485-487.	0.7	1
149	Rintatolimod (Ampligen \hat{A}^{\otimes}) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program. Cancers, 2022, 14, 1377.	1.7	1
150	Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. Journal of Clinical Oncology, 0, , .	0.8	1
151	Gastric Outlet Obstruction. JAMA Surgery, 2016, 151, 577.	2.2	0
152	Screening for colorectal cancer after pancreatoduodenectomy for ampullary cancer. European Journal of Surgical Oncology, 2020, 46, 534-538.	0.5	0
153	Endoscopic ultrasonography as additional preoperative workup is valuable in half of the patients with a pancreatic body or tail lesion. Hpb, 2021 , , .	0.1	0
154	Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report. Journal of Pancreatic Cancer, 2017, 3, 13-14.	1.6	0
155	Abstract PO-118: The tumor immune microenvironment is decisive in the survival of pancreatic ductal adenocarcinoma. , 2021 , , .		0
156	Abstract PO-046: The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: A prospective study of the PREOPANC-1 randomized controlled trial., 2021,,.		О